多种肿瘤相关自身抗体对肺癌的诊断价值OA

Objective:The research on the individual detection of various tumor-associated autoantibodies in serum and their combined detection in the clinical diagnostic value of lung cancer.Method:Totally 97 patients with a diagnosis of lung cancer,who were admitted to the First People's Hospital of Nanning from January 2022 to June 2023,were enrolled as the lung cancer group,82 patients diagnosed with non-lung cancer malignant tumors during the same period were selected as the non-lung cancer group,80 patients with benign lung lesions were selected as the benign lesion group,and 82 healthy individuals with no obvious lung abnormalities during physical examination were selected as the control group.Using the enzyme-linked immunosorbent assay(ELISA)to detect various tumor-associated autoantibodies in the serum of four groups of study subjects:P53 protein(P53),neuron-specific protein(PGP9.5),sex-determining region Y gene 2(SOX2),tumor-associated testis antigen 7(GAGE7),RNA helicase autoantibody 4-5(GBU4-5),melanoma-associated antigen A1(MAGE A1),and cancer-associated antigen(CAGE)expression levels.Comparing the expression levels of P53,PGP9.5,SOX2,GAGE7,GBU4-5,MAGE A1,and CAGE and the positive rate of combined detection among the four groups of study subjects.Analyzing the diagnostic value of P53,PGP9.5,SOX2,GAGE7,GBU4-5,MAGE A1,CAGE levels and combined detection in lung cancer patients.Result:The levels of P53,PGP9.5,SOX2,GAGE7,GBU4-5,MAGE A1,and CAGE in the lung cancer group were higher than the control group,showing significant differences(P<0.05).Relative to the non-lung cancer malignant tumor group,the lung cancer group revealed no statistically significant differences in the expression levels of PGP9.5,SOX2,GAGE7,GBU4-5,MAGE A1,and CAGE,apart from P53(P>0.05).Relative to the benign lung disease group,there were no statistically significant differences in the expression levels of the other autoantibodies previously mentioned in the lung cancer group,except for P53 and PGP9.5(P>0.05).The combined detection positive rates were 49.8%in the lung cancer group,26.8%in the Non-Lung Cancer Group,and 16.25%in the Benign Pulmonary Lesions Group,with statistically significant differences among the groups(P<0.05).Receiver Operating Characteristic(ROC)curve analysis revealed that the combined detection for lung cancer had a sensitivity of 69.1%,a specificity of 72.1%,and an area under the ROC curve(AUC)of 0.749,all of which were statistically significant(P<0.05).Conclusion:The combined detection of multiple tumor-related autoantibodies has certain diagnostic value for lung cancer.